U.S was the largest of Pfizer Inc’s 3 reported lines in fiscal 2025, at $74.16B — 59% of $125.16B.
| Geography | FY 2009 | FY 2010 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $86.63B | $56.29B | $74.16B | |||||||||||
| Us | — | — | — | |||||||||||
| United States | — | — | — | |||||||||||
| United States [Member} | — | — | — | |||||||||||
| Developed Markets | $81.07B | $41.82B | $32.38B | |||||||||||
| Developed Europe | — | — | — | |||||||||||
| Emerging Markets | $34.65B | $21.00B | $18.63B | |||||||||||
| Developed Rest Of World | — | — | — | |||||||||||
| Total | $202.35B | $119.11B | $125.16B |
In fiscal 2025, which ended December 31, 2025, the 3 regions Pfizer Inc reported in this breakdown added up to $125.16B. That was up 5.1% from $119.11B in fiscal 2023, the latest earlier year this breakdown was reported. U.S was the largest region, at $74.16B or 59.2% of the total, followed by Developed Markets ($32.38B, 25.9%) and Emerging Markets ($18.63B, 14.9%). Together, the two largest regions made up 85.1% of this total.
Compared with fiscal 2023, the latest earlier year reported, U.S grew the fastest, rising 31.7% to $74.16B. Developed Markets fell the most, down 22.6% to $32.38B. Over fiscal 2022 to 2025, revenue across these regions went from $202.35B to $125.16B, a compound annual decline of 14.8%. U.S's share of the total rose from 42.8% to 59.2% over the same years.
The table also keeps 5 regions that Pfizer Inc no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 14 fiscal years between 2009 and 2025, as reported in Pfizer Inc's annual filings.
Legacy Established Products was the largest of Pfizer Inc’s 4 reported lines in fiscal 2014, at $26.03B — 51% of $50.69B.
| Segment | FY 2014 |
|---|---|
| Legacy Established Products | $26.03B |
| Peri-Loe Products | $17.71B |
| Sterile Injectable Pharmaceuticals | $6.55B |
| Centreone | $396.00M |
| Total | $50.69B |
In fiscal 2014, which ended December 31, 2014, the 4 segments Pfizer Inc reported in this breakdown added up to $50.69B. Legacy Established Products was the largest segment, at $26.03B or 51.4% of the total, followed by Peri-Loe Products ($17.71B, 34.9%) and Sterile Injectable Pharmaceuticals ($6.55B, 12.9%). Together, the two largest segments made up 86.3% of this total.
This breakdown covers every fiscal year from 2014 to 2014, as reported in Pfizer Inc's annual filings.
All Other Biopharmaceutical Products was the largest of Pfizer Inc’s 50 reported lines in fiscal 2013, at $14.72B — 14% of $103.17B.
| Products and Services | FY 2009 | FY 2010 | FY 2012 | FY 2013 |
|---|---|---|---|---|
| Lipitor | $21.47B | $7.90B | $4.63B | |
| All Other Biopharmaceutical Products | $16.24B | $15.61B | $14.72B | |
| Prevnar Family | — | $8.23B | $7.95B | |
| Lyrica | $6.13B | $8.32B | $9.19B | |
| Alliance Revenues | $8.17B | $6.98B | $5.26B | |
| Animal Health | $7.15B | — | — | |
| Enbrel (Outside The U.S. & Canada) | $6.55B | $7.47B | $7.55B | |
| Celebrex | $4.75B | $5.44B | $5.84B | |
| Consumer Healthcare | $5.50B | $6.42B | $6.68B | |
| Prevnar 13/ Prevenar 13 | $4.83B | — | — | |
| Viagra | $3.86B | $4.10B | $3.76B | |
| Norvasc | $3.01B | $2.70B | $2.46B | |
| Zyvox | $2.35B | $2.69B | $2.71B | |
| Xalatan / Xalacom | $3.50B | $1.61B | $1.18B | |
| Sutent | $2.13B | $2.47B | $2.41B | |
| Geodon / Zeldox | — | — | — | |
| Premarin Family | $2.08B | $2.15B | $2.18B | |
| Genotropin | $1.77B | $1.66B | $1.54B | |
| Vfend | $1.65B | $1.51B | $1.55B | |
| Detrol / Detrol La | $2.03B | $1.52B | $1.12B | |
| Effexor | $3.44B | $850.00M | $880.00M | |
| Prevnar / Prevenar (7-Valent) | $2.51B | — | — | |
| Chantix / Champix | $1.51B | $1.34B | $1.30B | |
| Benefix | $1.29B | $1.55B | $1.66B | |
| Refacto Af/ Xyntha | $808.00M | $1.17B | $1.20B | |
| Zoloft | $1.06B | $1.08B | $938.00M | |
| Zosyn / Tazocin | $1.90B | $968.00M | $790.00M | |
| Medrol | $910.00M | $1.05B | $928.00M | |
| Pristiq | $932.00M | $1.26B | $1.40B | |
| Revatio | $962.00M | $1.07B | $614.00M | |
| Zithromax / Zmax | $830.00M | $870.00M | $774.00M | |
| Caduet | $1.05B | $516.00M | $446.00M | |
| Cardura | $826.00M | $676.00M | $592.00M | |
| Pfizer Centresource | — | — | — | |
| Aricept | $908.00M | $652.00M | $470.00M | |
| Fragmin | $682.00M | $762.00M | $718.00M | |
| Relpax | $646.00M | $736.00M | $718.00M | |
| Xanax Xr | $614.00M | — | — | |
| Other | $638.00M | $462.00M | $728.00M | |
| Aromasin | — | $420.00M | $370.00M | |
| Rapamune | $776.00M | $692.00M | $700.00M | |
| Neurontin | $644.00M | $470.00M | $432.00M | |
| Xanax/Xanax Xr | — | $548.00M | $552.00M | |
| Geodon | — | $706.00M | $388.00M | |
| Arthrotec | — | — | — | |
| Tygacil | $648.00M | $670.00M | $716.00M | |
| Diflucan | $556.00M | $518.00M | $484.00M | |
| Sulperazon | $426.00M | $524.00M | $618.00M | |
| B M P 2 | — | $526.00M | $418.00M | |
| Bmp2 | $800.00M | — | — | |
| Unasyn | $488.00M | $456.00M | $424.00M | |
| Dalacin / Cleocin | $428.00M | — | — | |
| Inlyta | — | $200.00M | $638.00M | |
| Xalkori | — | $246.00M | $564.00M | |
| Nutrition | — | — | — | |
| Inspra | $314.00M | $428.00M | $466.00M | |
| Somavert | $314.00M | $394.00M | $434.00M | |
| Depo-Provera | — | $296.00M | $382.00M | |
| Toviaz | $274.00M | $414.00M | $472.00M | |
| Xeljanz | — | $12.00M | $228.00M | |
| Methotrexate | — | — | — | |
| Total | $130.33B | $109.31B | $103.17B |
In fiscal 2013, which ended December 31, 2013, the 50 revenue lines Pfizer Inc reported in this breakdown added up to $103.17B. That was down 5.6% from $109.31B in fiscal 2012. All Other Biopharmaceutical Products was the largest revenue line, at $14.72B or 14.3% of the total, followed by Lyrica ($9.19B, 8.9%) and Prevnar Family ($7.95B, 7.7%). Together, the two largest revenue lines made up 23.2% of this total.
Compared with fiscal 2012, Lyrica grew the fastest, rising 10.5% to $9.19B. Lipitor fell the most, down 41.4% to $4.63B.
Prevnar Family (fiscal 2012), Xanax/Xanax Xr (fiscal 2012), Geodon (fiscal 2012) and B M P 2 (fiscal 2012) were first reported as separate revenue lines during this period. The table also keeps 11 revenue lines that Pfizer Inc no longer reports, so earlier years can still be read on their original basis; use "Show 11 discontinued" beneath the table to see them. This breakdown covers 4 fiscal years between 2009 and 2013, as reported in Pfizer Inc's annual filings.
Pfizer Inc (PFE) breaks its revenue down by region, segment and revenue line. In fiscal 2025, its largest region was U.S, with $74.16B or 59.2% of the total, followed by Developed Markets at $32.38B (25.9%).
U.S was Pfizer Inc's largest region in fiscal 2025, with $74.16B in revenue, 59.2% of the $125.16B reported across its 3 regions.
Legacy Established Products was Pfizer Inc's largest segment in fiscal 2014, with $26.03B in revenue, 51.4% of the $50.69B reported across its 4 segments.
All Other Biopharmaceutical Products was Pfizer Inc's largest revenue line in fiscal 2013, with $14.72B in revenue, 14.3% of the $103.17B reported across its 50 revenue lines.
Of the Pfizer Inc revenue lines reported in both fiscal 2012 and fiscal 2013, and making up at least 2% of the total, Lyrica grew the fastest, rising 10.5% from $8.32B to $9.19B.
Every figure is taken from Pfizer Inc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2009 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.